← Oncology Approval Tracker

FDA DECISION ·

Tecartus

brexucabtagene autoleucel · Kite Pharma

Accelerated approvalNew therapyMantle cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Apr 1, 2026

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with relapsed or refractory mantle cell lymphoma.

LAMPGEN ANALYSIS

Why it matters

Introduced CD19-directed CAR T-cell therapy for mantle cell lymphoma under accelerated approval.

What research teams should watch

Plan leukapheresis, manufacturing and bridging care and confirm readiness for early toxicity monitoring.

PRIMARY RECORDS

Sources